阿克里多尼作为对抗奥罗普什病毒的有希望的候选药物
Marielena Vogel Saivish1, Gabriela de Lima Menezes2,3, Roosevelt Alves da Silva2
1Laboratório de Pesquisas em Virologia, Departamento de Doenças Dermatológicas, Infecciosas e Parasitárias, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP 15090-000, Brazil.
Current research in microbial sciences
|January 18, 2024
概括
阿克里化合物显示出作为抗病毒药物的显著潜力,在体外抑制Oropouche病毒 (OROV) 复制率99.9%. 这一发现为开发针对这个被忽视的树冠病毒的治疗方法提供了一个有希望的新途径.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 分子生物学分子生物学
背景情况:
- 耳鼻病毒 (OROV) 是一种新兴的树冠病毒,在南美洲引起耳鼻热,自1955年以来已诊断出超过50万例.
- 目前的预防依赖于对被忽视的病毒的有限疫苗,没有针对OROV的特定抗病毒治疗方法.
- 破坏病毒复制机制为控制OROV传播提供了一个替代策略.
研究的目的:
- 研究阿克里化合物的抗病毒潜力,以对抗Oropouche病毒 (OROV).
- 阐明阿克里在抑制病毒复制中的作用机制.
- 探索基于阿克里分子的新一代抗病毒药物的开发.
主要方法:
- 在体外测试阿克里化合物用于抑制OROV复制.
- 对病毒复制中间体的分析,包括双链RNA (dsRNA).
- 分子动力学 (MD) 模拟,对接和结合自由能量分析以评估分子相互作用.
主要成果:
- 阿克里化合物显著抑制OROV复制,在体外达到高达99.9%的减少.
- 一种特定的化合物FAC21与OROV内核酶有强烈的相互作用,可能阻碍病毒RNA与蛋白相互作用.
- 证据表明抗病毒作用的双重机制,可能涉及dsrna插曲.
结论:
- 阿克里顿是Oropouche病毒复制的有效抑制剂.
- FAC21与OROV内核酶的相互作用是其抗病毒活性的一个关键因素.
- 基于阿克里的分子代表了开发针对OROV的新型抗病毒疗法的有希望的基础.
相关概念视频
02:27DNA Base Pairing
Erwin Chargaff’s rules on DNA equivalence paved the way for the discovery of base pairing in DNA. Chargaff’s rules state that in a double-stranded DNA molecule,
01:29Subviral Agents
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...